Cervical cancer is the third most frequent cancer in women worldwide, mostly treated with 24 cisplatin-based chemoradiotherapy. Since it is known that folate metabolism might interfere with cisplatin 25 effectiveness, we intended to study the influence of the Gamma Glutamyl Hydrolase -401C > T polymorphism 26 in treatment response in cervical cancer. 27 Methods: We retrospectively reviewed the clinical data of 167 patients with bulky cervical cancer submitted 28 to cisplatin-based chemoradiotherapy. The genotypes of GGH -401C > T SNP were determined by real-time 29 PCR and statistical analysis was performed by χ 2 test and survival analysis.
U N C O R R E C T E D P R O O F 1
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The impact of GGH -401C > T polymorphism on cisplatin-based chemoradiotherapy cancer stages (IB2-IVA FIGO stages) (Candelaria et al., 2006; Ferlay et al., 2010; Tewari and Monk, 2010 and dosing have yet to be established due to the frequent development 51 of therapy resistance (Candelaria et al., 2006 have been studied (Kim et al., 2008) . 
With this study, we intended to investigate the influence of the GGH − 
(χ 2 = 0.32). Genotypic differences between cancer subtypes were addi- (Fig. 1) . 
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Since the GGH -401C> T polymorphism leads to GGH overexpression,
189
we thought that an impairment in folate metabolism might activate com- ports our suggestion (Lu et al., 1988; Scanlon and Kashani-Sabet, 1988; 197 Whiteside et al., 2006) . 
